摘要:
This invention is concerned with novel compounds represented by structural formula I ##STR1## where X and Y are independently hydrogen, chloro, fluoro, bromo, iodo, or trifluoromethyl and n is 0, 1 or 2;R is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy; andthe racemates, mixtures of enantiomers, individual diastereomers or individual enantiomers with all isomeric forms and pharmaceutically acceptable salts, hydrates or crystal forms thereof, which are antiarrhythmic agents.
摘要:
Compounds of the general structural formula: ##STR1## or a pharmaceutically acceptable salt, hydrate or crystal form thereof, wherein;X is O or CH.sub.2R.sup.1 is H if R.sup.2 is not H or if R.sup.2 is H then R.sup.1 is ##STR2## R.sup.2 is --H if R.sup.1 is not H or if R.sup.1 is H then R.sup.2 is; ##STR3## and R.sup.3 is ##STR4## are Class HI antiarrhythmic agents.
摘要:
Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
摘要:
A method for inhibiting transglutaminase activity, especially Factor XIIIa activity with certain imidazole compounds is described. The imidazole compounds are those selected from(A) a imidazole having the formula ##STR1## or its acid addition salt, and ##STR2## wherein: R is hydrogen or lower alkyl;R.sup.1 is lower alkyl;R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl;R.sup.4 is lower alkyl; andX is the negative radical of a pharmaceutically acceptable salt.Also described are compositions suitable for use in inhibiting transglutaminase activity.
摘要:
The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
摘要:
Compounds represented by Formula (I): (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain
摘要:
There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.